332 related articles for article (PubMed ID: 19921535)
1. The kynurenine pathway and inflammation in amyotrophic lateral sclerosis.
Chen Y; Stankovic R; Cullen KM; Meininger V; Garner B; Coggan S; Grant R; Brew BJ; Guillemin GJ
Neurotox Res; 2010 Aug; 18(2):132-42. PubMed ID: 19921535
[TBL] [Abstract][Full Text] [Related]
2. Involvement of the kynurenine pathway in human glioma pathophysiology.
Adams S; Teo C; McDonald KL; Zinger A; Bustamante S; Lim CK; Sundaram G; Braidy N; Brew BJ; Guillemin GJ
PLoS One; 2014; 9(11):e112945. PubMed ID: 25415278
[TBL] [Abstract][Full Text] [Related]
3. Activation of the kynurenine pathway and increased production of the excitotoxin quinolinic acid following traumatic brain injury in humans.
Yan EB; Frugier T; Lim CK; Heng B; Sundaram G; Tan M; Rosenfeld JV; Walker DW; Guillemin GJ; Morganti-Kossmann MC
J Neuroinflammation; 2015 May; 12():110. PubMed ID: 26025142
[TBL] [Abstract][Full Text] [Related]
4. Implications for the kynurenine pathway and quinolinic acid in amyotrophic lateral sclerosis.
Guillemin GJ; Meininger V; Brew BJ
Neurodegener Dis; 2005; 2(3-4):166-76. PubMed ID: 16909022
[TBL] [Abstract][Full Text] [Related]
5. A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate.
Heyes MP; Saito K; Major EO; Milstien S; Markey SP; Vickers JH
Brain; 1993 Dec; 116 ( Pt 6)():1425-50. PubMed ID: 8293279
[TBL] [Abstract][Full Text] [Related]
6. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression.
Raison CL; Dantzer R; Kelley KW; Lawson MA; Woolwine BJ; Vogt G; Spivey JR; Saito K; Miller AH
Mol Psychiatry; 2010 Apr; 15(4):393-403. PubMed ID: 19918244
[TBL] [Abstract][Full Text] [Related]
7. Involvement of quinolinic acid in the neuropathogenesis of amyotrophic lateral sclerosis.
Lee JM; Tan V; Lovejoy D; Braidy N; Rowe DB; Brew BJ; Guillemin GJ
Neuropharmacology; 2017 Jan; 112(Pt B):346-364. PubMed ID: 27265569
[TBL] [Abstract][Full Text] [Related]
8. Dynamic changes in kynurenine pathway metabolites in multiple sclerosis: A systematic review.
Fathi M; Vakili K; Yaghoobpoor S; Tavasol A; Jazi K; Mohamadkhani A; Klegeris A; McElhinney A; Mafi Z; Hajiesmaeili M; Sayehmiri F
Front Immunol; 2022; 13():1013784. PubMed ID: 36426364
[TBL] [Abstract][Full Text] [Related]
9. Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms.
Schefold JC; Zeden JP; Fotopoulou C; von Haehling S; Pschowski R; Hasper D; Volk HD; Schuett C; Reinke P
Nephrol Dial Transplant; 2009 Jun; 24(6):1901-8. PubMed ID: 19155537
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in the treatment of amyotrophic lateral sclerosis. Emphasis on kynurenine pathway inhibitors.
Chen Y; Meininger V; Guillemin GJ
Cent Nerv Syst Agents Med Chem; 2009 Mar; 9(1):32-9. PubMed ID: 20021336
[TBL] [Abstract][Full Text] [Related]
11. Changes in kynurenine pathway metabolism in the brain, liver and kidney of aged female Wistar rats.
Braidy N; Guillemin GJ; Mansour H; Chan-Ling T; Grant R
FEBS J; 2011 Nov; 278(22):4425-34. PubMed ID: 22032336
[TBL] [Abstract][Full Text] [Related]
12. Involvement of Indoleamine-2,3-Dioxygenase and Kynurenine Pathway in Experimental Autoimmune Encephalomyelitis in Mice.
Zarzecki MS; Cattelan Souza L; Giacomeli R; Silva MRP; Prigol M; Boeira SP; Jesse CR
Neurochem Res; 2020 Dec; 45(12):2959-2977. PubMed ID: 33040279
[TBL] [Abstract][Full Text] [Related]
13. An enzyme in the kynurenine pathway that governs vulnerability to suicidal behavior by regulating excitotoxicity and neuroinflammation.
Brundin L; Sellgren CM; Lim CK; Grit J; Pålsson E; Landén M; Samuelsson M; Lundgren K; Brundin P; Fuchs D; Postolache TT; Traskman-Bendz L; Guillemin GJ; Erhardt S
Transl Psychiatry; 2016 Aug; 6(8):e865. PubMed ID: 27483383
[TBL] [Abstract][Full Text] [Related]
14. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Tan L; Yu JT; Tan L
J Neurol Sci; 2012 Dec; 323(1-2):1-8. PubMed ID: 22939820
[TBL] [Abstract][Full Text] [Related]
15. Treatment with granulocyte-macrophage colony-stimulating factor is associated with reduced indoleamine 2,3-dioxygenase activity and kynurenine pathway catabolites in patients with severe sepsis and septic shock.
Schefold JC; Zeden JP; Pschowski R; Hammoud B; Fotopoulou C; Hasper D; Fusch G; Von Haehling S; Volk HD; Meisel C; Schütt C; Reinke P
Scand J Infect Dis; 2010 Mar; 42(3):164-71. PubMed ID: 19958238
[TBL] [Abstract][Full Text] [Related]
16. Some CSF Kynurenine Pathway Intermediates Associated with Disease Evolution in Amyotrophic Lateral Sclerosis.
Alarcan H; Chaumond R; Emond P; Benz-De Bretagne I; Lefèvre A; Bakkouche SE; Veyrat-Durebex C; Vourc'h P; Andres C; Corcia P; Blasco H
Biomolecules; 2021 May; 11(5):. PubMed ID: 34063031
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the kynurenine pathway in NSC-34 cell line: implications for amyotrophic lateral sclerosis.
Chen Y; Brew BJ; Guillemin GJ
J Neurochem; 2011 Sep; 118(5):816-25. PubMed ID: 21182524
[TBL] [Abstract][Full Text] [Related]
18. LC-MS/MS-based quantification of kynurenine metabolites, tryptophan, monoamines and neopterin in plasma, cerebrospinal fluid and brain.
Fuertig R; Ceci A; Camus SM; Bezard E; Luippold AH; Hengerer B
Bioanalysis; 2016 Sep; 8(18):1903-17. PubMed ID: 27524289
[TBL] [Abstract][Full Text] [Related]
19. A novel, robust method for quantification of multiple kynurenine pathway metabolites in the cerebrospinal fluid.
Schwieler L; Trepci A; Krzyzanowski S; Hermansson S; Granqvist M; Piehl F; Venckunas T; Brazaitis M; Kamandulis S; Lindqvist D; Jones AD; Erhardt S; Brundin L
Bioanalysis; 2020 Mar; 12(6):379-392. PubMed ID: 32209024
[No Abstract] [Full Text] [Related]
20. Increased 3-hydroxykynurenine serum concentrations differentiate Alzheimer's disease patients from controls.
Schwarz MJ; Guillemin GJ; Teipel SJ; Buerger K; Hampel H
Eur Arch Psychiatry Clin Neurosci; 2013 Jun; 263(4):345-52. PubMed ID: 23192697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
